Antipsychotic-induced epigenomic reorganization in frontal cortex of individuals with schizophrenia
- Department of Chemical Engineering, Virginia Tech, United States
- Department of Chemistry and Biochemistry, University of California, San Diego, United States
- Department of Biomedical Engineering and Mechanics, Virginia Tech, United States
- Department of Physiology and Biophysics, Virginia Commonwealth University School of Medicine, United States
- Department of Pharmacology, University of the Basque Country UPV/EHU, CIBERSAM, Biocruces Health Research Institute, Spain
- Department of Cellular and Molecular Medicine, University of California, San Diego, United States
Figures
Figure 1 with 7 supplements
Overview of the multi-omics protocol for analyzing frontal cortex of schizophrenia subjects and controls.
(A) Overview of the experimental design starting from postmortem human frontal cortex samples to generate cell type-specific H3K27ac, H3K4me3, and RNA profiles. (B) Heatmap of the expression of …
Figure 1—figure supplement 1
Distribution of six quality control metrics for ChIP-seq data on H3K4me3 and H3K27ac in NeuN-positive (NeuN+) and NeuN-negative (NeuN-) nuclei from schizophrenia and control groups, respectively.
(A) Number of uniquely mapped reads obtained by bowtie2 and bedtools. (B) Fraction of reads in peaks (FRiP) obtained by featureCounts. (C) PCR Bottleneck Coefficient (PBC) obtained by encodeChIPqc. …
Figure 1—figure supplement 2
Saturation curves on the relationship between the number of sequencing reads and the number of identified peaks with our ChIP-seq data on H3K4me3 and H3K27ac.
Figure 1—figure supplement 3
Distribution of four quality control metrics for RNA-seq data in NeuN-positive (NeuN+) and NeuN-negative (NeuN-) nuclei from schizophrenia and control groups.
(A) Number of uniquely mapped reads. (B) Aligned rate. (C) Percentage of reads overlapping exons. (D) Deduplicate rate (percentage of unique reads).
Figure 1—figure supplement 4
Representative results from fluorescence-activated cell sorting (FACS) sorting demonstrating the separation of neuronal (NeuN+) and non-neuronal (NeuN-) nuclei using fluorescence-labeled anti-NeuN antibody in postmortem human frontal cortex samples.
Figure 1—figure supplement 5
Expression of neuronal (NeuN+) and non-neuronal (NeuN-) representative marker genes.
Comparative bar plots with the expression of neuronal (A and B) and glial (C and D) cell markers in both NeuN-positive (NeuN+) and NeuN-negative (NeuN-) frontal cortex samples from 29 control …
Figure 1—figure supplement 6
Venn diagrams of the overlap between the identified peaks from our ChIP-seq study (green) and previous datasets (Girdhar et al., 2022) (cyan).
(A) H3K27ac peak overlap (Mb) between our study (NeuN-positive, NeuN+) and previous datasets (NeuN+). (B) H3K27ac peak overlap (Mb) between our study (NeuN+) and previous datasets (bulk). (C) …
Figure 1—figure supplement 7
Visualization of peak-wise or gene-wise means and variances of ChIP-seq and RNA-seq data, respectively, by voom plots.
The LOWESS curves (red lines) indicate the smooth mean-variance trend. (A) ChIP-seq data on H3K4me3 from NeuN-positive (NeuN+) nuclei. (B) ChIP-seq data on H3K4me3 from NeuN-negative (NeuN-) nuclei. …
Figure 2 with 2 supplements
Comparison of epigenomic and transcriptomic landscapes in the frontal cortex of schizophrenia subjects and controls.
(A) Differential enhancer/promoter peaks and differentially expressed genes (DEGs) obtained by comparing schizophrenia (n=29) and controls (n=29). The differential peaks or DEGs were identified …
Figure 2—figure supplement 1
qPCR validation of selected differential ChIP-seq peaks in NeuN+ fraction for H3K27ac (a-c) and H3K4me3 (d-f).
ChIP DNA yielded by MOWChIP assays was examined by qPCR. Primers were designed for each peak (see Methods) and amplicon regions were marked by a black bar under genome browser tracks. A common …
Figure 2—figure supplement 2
Q-Q plots of the corrected p-value from differential peaks at enhancer/promoter regions and differentially expressed genes.
(A) Differential enhancer peaks from NeuN-positive (NeuN+) nuclei. (B) Differential enhancer peaks from NeuN-negative (NeuN-) nuclei. (C) Differential promoter peaks from NeuN+ nuclei. (D) …
Figure 3
Genome-wide multidimensional clusters in the frontal cortex of schizophrenia subjects and controls.
(A) Integrative analysis using EpiSig. 814 EpiSig clusters across 348 genome-wide sequencing datasets were grouped into 6 sections. The heatmap shows the signal in each EpiSig cluster (row: EpiSig …
Figure 4
Transcriptional regulatory processes in the frontal cortex of schizophrenia subjects and controls.
(A) Heatmap of z-score Personalized PageRank (PPR) for top 10 significantly differentially expressed transcription factors (TFs) (FDR <0.05) ranked by absolute change in PPR for NeuN-positive (NeuN+)…
Figure 5 with 4 supplements
Epigenomic alterations affected by antipsychotic treatment.
(A) Scatter plot of average pairwise change in Personalized PageRank (PPR) (PPRschizophrenia – PPRcontrol) for antipsychotic-free (AF) vs antipsychotic-treated (AT) NeuN-positive (NeuN+) cohorts. …
Figure 5—figure supplement 1
Uniform manifold approximation and projection (UMAP) visualization of the feature matrix of enhancers, promoters, and RNA among antipsychotic-free (AF)-schizophrenia, antipsychotic-treated (AT)-schizophrenia, and control subjects.
Figure 5—figure supplement 2
Differential peak enrichment analysis for antipsychotic-free NeuN-positive (NeuN+) nuclei in EpiSig clusters.
(a) Percentage of total antipsychotic-free (AF)-specific differential H3K27ac peaks in the 22 significantly enriched (FDR <0.05) EpiSig clusters. Top three clusters 630, 732 (Section 1) and 449 …
Figure 5—figure supplement 3
Differential peak enrichment analysis for antipsychotic-treated NeuN-positive (NeuN+) nuclei in EpiSig clusters.
(a) Percentage of total antipsychotic-treated (AT)-specific differential H3K27ac peaks in the 99 significantly enriched (FDR <0.05) EpiSig clusters. Top two clusters 6 and 8 (Section 4) highlighted …
Figure 5—figure supplement 4
Differential peak enrichment analysis for antipsychotic-treated NeuN-negative (NeuN-) nuclei in EpiSig clusters.
(a) Percentage of total antipsychotic-treated (AT)-specific differential H3K27ac peaks in the 72 significantly enriched (FDR <0.05) EpiSig clusters. Top two clusters 582 (Section 6) and 703 (Section …
Figure 6
Effect of antipsychotic treatment on differential enhancers/promoters and differentially expressed genes (DEGs) in NeuN-positive (NeuN+) and NeuN-negative (NeuN-) nuclei from the frontal cortex of schizophrenia subjects and controls.
(A) Differential enhancer/promoter peaks and DEGs were obtained by comparing antipsychotic-free (AF)-schizophrenics and individually matched controls. (B) Differential enhancer/promoter peaks and …
Figure 7
Epigenomic effect of age on treated schizophrenia subjects.
(A) Violin plots for Pearson’s R correlation coefficients of age vs expression f 742, 622, and 242 genes from control, antipsychotic-free (AF)-schizophrenia, and antipsychotic-treated …
Additional files
-
Supplementary file 1
Demographic information of antipsychotic-free (AF)-schizophrenia subjects and controls.
- https://cdn.elifesciences.org/articles/92393/elife-92393-supp1-v1.doc
-
Supplementary file 2
Demographic information of antipsychotic-treated (AT)-schizophrenia subjects and controls.
- https://cdn.elifesciences.org/articles/92393/elife-92393-supp2-v1.doc
-
Supplementary file 3
Quality control measurements on ChIP-seq datasets.
- https://cdn.elifesciences.org/articles/92393/elife-92393-supp3-v1.xls
-
Supplementary file 4
Quality control measurements on RNA-seq datasets.
- https://cdn.elifesciences.org/articles/92393/elife-92393-supp4-v1.xlsx
-
Supplementary file 5
Transcription frequency in transcripts per kilobase million (TPM) on key marker genes for neuronal and glial nuclei samples from control and schizophrenia subjects.
- https://cdn.elifesciences.org/articles/92393/elife-92393-supp5-v1.xlsx
-
Supplementary file 6
Differential histone modification peaks and differentially expressed genes (DEGs) obtained by comparing schizophrenia and controls.
- https://cdn.elifesciences.org/articles/92393/elife-92393-supp6-v1.xlsx
-
Supplementary file 7
Enrichment of various genome-wide association studies (GWAS) traits in differential enhancers and promoters.
- https://cdn.elifesciences.org/articles/92393/elife-92393-supp7-v1.docx
-
Supplementary file 8
Overlap of differentially expressed genes (DEGs) identified in our study and a previous snRNA-seq study.
- https://cdn.elifesciences.org/articles/92393/elife-92393-supp8-v1.xlsx
-
Supplementary file 9
Genes identified via differential analyses of enhancers, promoters, and RNA by comparing schizophrenia and controls.
- https://cdn.elifesciences.org/articles/92393/elife-92393-supp9-v1.xlsx
-
Supplementary file 10
EpiSig analysis in NeuN-positive (NeuN+) nuclei from the frontal cortex of schizophrenia subjects and controls.
- https://cdn.elifesciences.org/articles/92393/elife-92393-supp10-v1.xlsx
-
Supplementary file 11
EpiSig analysis in NeuN-negative (NeuN-) nuclei from the frontal cortex of schizophrenia subjects and controls.
- https://cdn.elifesciences.org/articles/92393/elife-92393-supp11-v1.xlsx
-
Supplementary file 12
Taiji analysis in NeuN-positive (NeuN+) and NeuN-negative (NeuN-) nuclei from the frontal cortex of schizophrenia subjects and controls.
- https://cdn.elifesciences.org/articles/92393/elife-92393-supp12-v1.xlsx
-
Supplementary file 13
Taiji analysis in NeuN-positive (NeuN+)and NeuN-negative (NeuN-) nuclei from the frontal cortex of antipsychotic-free (AF)-schizophrenia subjects, antipsychotic-treated (AT)-schizophrenia subjects, and controls.
- https://cdn.elifesciences.org/articles/92393/elife-92393-supp13-v1.xlsx
-
Supplementary file 14
EpiSig analysis in NeuN-positive (NeuN+) nuclei from the frontal cortex of antipsychotic-free (AF)-schizophrenia subjects and controls.
- https://cdn.elifesciences.org/articles/92393/elife-92393-supp14-v1.xlsx
-
Supplementary file 15
Differential H3K27ac/H3K4me3 peaks and DEGs obtained by comparing antipsychotic-free (AF)-schizophrenia and antipsychotic-treated (AT)-schizophrenia with their respective matched controls.
- https://cdn.elifesciences.org/articles/92393/elife-92393-supp15-v1.xlsx
-
Supplementary file 16
Genes altered in antipsychotic-free (AF-) but not antipsychotic-treated (AT)-schizophrenics, and those altered in AT- but not AF-schizophrenics.
The lists of genes were obtained by differential analyses of enhancers, promoters, and RNA in AF-schizophrenia, AT-schizophrenia, and their respective controls.
- https://cdn.elifesciences.org/articles/92393/elife-92393-supp16-v1.xlsx
-
Supplementary file 17
EpiSig analysis in NeuN-positive (NeuN+) nuclei from the frontal cortex of antipsychotic-treated (AT)-schizophrenia subjects and controls.
- https://cdn.elifesciences.org/articles/92393/elife-92393-supp17-v1.xlsx
-
Supplementary file 18
EpiSig analysis in NeuN-negative (NeuN-) nuclei from the frontal cortex of antipsychotic-treated (AT)-schizophrenia subjects and controls.
- https://cdn.elifesciences.org/articles/92393/elife-92393-supp18-v1.xlsx
-
Supplementary file 19
Effect of age on chromatin organization in the frontal cortex of AF-schizophrenia subjects, AT-schizophrenia subjects, and controls.
- https://cdn.elifesciences.org/articles/92393/elife-92393-supp19-v1.xlsx
-
Supplementary file 20
Toxicological analysis in postmortem human brain samples.
- https://cdn.elifesciences.org/articles/92393/elife-92393-supp20-v1.xlsx
-
MDAR checklist
- https://cdn.elifesciences.org/articles/92393/elife-92393-mdarchecklist1-v1.docx
